China SXT Pharmaceuticals Inc Working Capital to Net Assets Ratio
China SXT Pharmaceuticals Inc working capital to net assets ratio. China SXT Pharmaceuticals Inc (SXTC) has a Working Capital to Net Assets ratio of 101.5% as of June 2026. Working capital of $30.16 Million (current assets of $34.51 Million minus current liabilities of $4.35 Million) is measured against net assets of $29.71 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check SXTC goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of China SXT Pharmaceuticals Inc (2016–2026)
Working capital to net assets ratio of China SXT Pharmaceuticals Inc from 2016 to 2026. This chart shows how China SXT Pharmaceuticals Inc's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2016 to 2026. As of June 2026, the ratio stands at 101.5%, reflecting working capital of $30.16 Million against net assets of $29.71 Million USD. See SXTC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
China SXT Pharmaceuticals Inc Working Capital to Net Assets Ratio by Year (2016–2026)
China SXT Pharmaceuticals Inc working capital to net assets ratio by year from 2016 to 2026. The table below presents the year-by-year Working Capital to Net Assets ratio for China SXT Pharmaceuticals Inc from 2016 to 2026, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see SXTC asset base.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2026 | 101.5% | $30.16 Million | $29.71 Million | $34.51 Million | $4.35 Million | ▲ +2.5 pp |
| 2025 | 99.0% | $15.28 Million | $15.44 Million | $21.30 Million | $6.01 Million | ▲ +60.7 pp |
| 2024 | 38.3% | $5.33 Million | $13.93 Million | $14.23 Million | $8.90 Million | ▲ +4.1 pp |
| 2023 | 34.2% | $5.02 Million | $14.69 Million | $19.52 Million | $14.50 Million | ▲ +1.7 pp |
| 2022 | 32.5% | $5.33 Million | $16.42 Million | $22.45 Million | $17.12 Million | ▲ +3.3 pp |
| 2021 | 29.2% | $4.65 Million | $15.96 Million | $23.23 Million | $18.58 Million | ▼ -49.3 pp |
| 2020 | 78.4% | $7.37 Million | $9.40 Million | $19.64 Million | $12.26 Million | ▼ -5.0 pp |
| 2019 | 83.4% | $9.27 Million | $11.11 Million | $15.59 Million | $6.32 Million | ▲ +30.8 pp |
| 2018 | 52.7% | $1.73 Million | $3.29 Million | $6.10 Million | $4.37 Million | ▼ -18.9 pp |
| 2017 | 71.6% | $1.33 Million | $1.85 Million | $4.91 Million | $3.58 Million | ▲ +47.3 pp |
| 2016 | 24.3% | $180.22K | $742.77K | $5.73 Million | $5.55 Million | — |